Rentschler Biotechnologie GmbH & Co. Appoints Stefan Rampf To The Position Of CFO

Laupheim, Germany, February 15, 2016 / B3C newswire / -- Rentschler Biotechnologie, a leading contract organization for the development and manufacturing of biopharmaceuticals announces the appointment of Stefan Rampf as new Chief Financial Officer (CFO) effective May 1st, 2016.

Stefan Rampf will be responsible for Commercial Management. The 49-year-old has about one decade's experience as CFO with renowned companies, most recently with ABL Technik Entlackung GmbH, Leutkirch, and, until 2013, with Volvo Financial Services in Frankfurt.

Dr. Nikolaus F. Rentschler: "Stefan Rampf convinces through his excellent expertise and strengthens the Top Management of Rentschler Biotechnologie on its successful way. The Supervisory Board and Management Board are very much looking forward to the cooperation."

Dr. Frank Mathias: "With Stefan Rampf joining Rentschler, the new Management Board will be complete. Together with Thomas Siklosi and the whole Management Team we will continue our close and successful cooperation with our partners and clients and jointly bring the company forward."

About Rentschler Biotechnologie

Rentschler is a full-service Contract Development and Manufacturing Organization (CDMO) and one of the leaders in the industry. With many years of experience the company is a reliable outsourcing partner. Focused on mammalian cell lines, the experience covers the development and manufacturing of biopharmaceuticals for clients, supporting them through to market approval of their products. The high quality of the consulting services and the competent implementation of cGMP and quality management standards ensure the project success. Cutting-edge technologies and cGMP facilities with stainless steel and single-use bioreactors support the flexible and customized cost-efficient manufacturing for clinical studies and market supply. Rentschler is a privately owned company which can act independently on a long-term basis.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.